Page last updated: 2024-11-03

rabeprazole and ER-Negative PR-Negative HER2-Negative Breast Cancer

rabeprazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Research Excerpts

ExcerptRelevanceReference
" We here investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model."1.39The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. ( Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bello, E1
Taraboletti, G1
Colella, G1
Zucchetti, M1
Forestieri, D1
Licandro, SA1
Berndt, A1
Richter, P1
D'Incalci, M1
Cavalletti, E1
Giavazzi, R1
Camboni, G1
Damia, G1

Other Studies

1 other study available for rabeprazole and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:2

    Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism;

2013